Oslo, 9 July

Reference is made to the announcement by Observe Medical ASA (the "Company" or
"Observe Medical", OSE ticker "OBSVR") on 3 July 2025, regarding the resolution
by the extraordinary the general meeting to increase the Company's share capital
in connection with a private placement (the "Private Placement") by the issuance
of (i) 56,890,000 new shares to investors in the Private Placement and (ii)
10,000,000 new shares to Navamedic ASA in connection with a loan conversion
(together the "Offer Shares").

The share capital increase pertaining to the Offer Shares, has today been
registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret).

The Company's share capital is NOK 38,702,333.04, divided into 92,148,412
shares, each with a nominal value of NOK 0.42.

The Offer Shares will be registered with the Norwegian Central Securities
Depository Euronext Securities Oslo (the "VPS") on a separate ISIN from the
existing shares of the Company, pending approval and publication by the Company
of a prospectus (the "Prospectus") and will thus not be tradable on Euronext
Expand Oslo until the Prospectus has been approved by the Financial Supervisory
Authority of Norway (the "NFSA") and published by the Company, upon which the
Offer Shares will be transferred to the Company's ordinary ISIN in the VPS and
be admitted to trading on Euronext Expand Oslo. The Prospectus is expected to be
approved by the NFSA and published by the Company at the end of Q3 2025.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.